Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ceriello, A.
Right arrow Articles by Bartoli, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ceriello, A.
Right arrow Articles by Bartoli, E.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 44, Issue 8 924-928, Copyright © 1995 by American Diabetes Association


ARTICLES

Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress

A Ceriello, R Giacomello, G Stel, E Motz, C Taboga, L Tonutti, M Pirisi, E Falleti and E Bartoli
Department of Clinical and Experimental Pathology and Medicine, University of Udine, Italy.

Diabetes is characterized by the existence of a thrombosis-prone condition, possibly related to hyperglycemia. However, the mechanism linking hyperglycemia to the activation of the coagulation cascade is still unclear. It has been recently suggested that diabetes is accompanied by increased oxidative stress. In this work, the possibility that oxidative stress may be involved in the hyperglycemia-induced coagulation activation has been evaluated. Prothrombin fragment 1 + 2 (F1 + 2), which represents a reliable marker of the amount of thrombin released in the circulation, has been chosen for studying thrombin formation in vivo. In nine type II diabetic patients and in seven healthy control subjects, matched for age and body mass index, three different experiments were performed: oral glucose tolerance test (OGTT), intravenous antioxidant glutathione (GSH) administration for 2 h, and OGTT plus intravenous GSH administration. Samples were drawn at -15 min and every 30 min from 0 to 180 min. During the OGTT, F1 + 2 significantly increased in both diabetic and healthy subjects. GSH administration during OGTT normalized this phenomenon. GSH administration alone significantly decreased F1 + 2 in diabetic patients, while no effect was observed in the normal subjects. These data suggest that hyperglycemia may induce thrombin activation, possibly inducing an oxidative stress, and that antioxidant GSH may counterbalance this effect.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Eur Heart J SupplHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74.
[Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J., January 1, 2007; 28(1): 88 - 136.
[Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
J. W. A. Smit and J. A. Romijn
Acute insulin resistance in myocardial ischemia: causes and consequences.
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 215 - 219.
[Abstract] [PDF]


Home page
DiabetesHome page
M. E. Stegenga, S. N. van der Crabben, M. Levi, A. F. de Vos, M. W. Tanck, H. P. Sauerwein, and T. van der Poll
Hyperglycemia Stimulates Coagulation, Whereas Hyperinsulinemia Impairs Fibrinolysis in Healthy Humans
Diabetes, June 1, 2006; 55(6): 1807 - 1812.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
V. R. Vaidyula, A. K. Rao, M. Mozzoli, C. Homko, P. Cheung, and G. Boden
Effects of Hyperglycemia and Hyperinsulinemia on Circulating Tissue Factor Procoagulant Activity and Platelet CD40 Ligand
Diabetes, January 1, 2006; 55(1): 202 - 208.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Ceriello
Acute hyperglycaemia: a 'new' risk factor during myocardial infarction
Eur. Heart J., February 2, 2005; 26(4): 328 - 331.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
A. Ceriello
Postprandial Hyperglycemia and Diabetes Complications: Is It Time to Treat?
Diabetes, January 1, 2005; 54(1): 1 - 7.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
M E Tushuizen, M Diamant, and R J Heine
Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes
Postgrad. Med. J., January 1, 2005; 81(951): 1 - 6.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
C.-c. Hsu, H.-f. Yen, M.-c. Yin, C.-m. Tsai, and C.-h. Hsieh
Five Cysteine-Containing Compounds Delay Diabetic Deterioration in Balb/cA Mice
J. Nutr., December 1, 2004; 134(12): 3245 - 3249.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
P. Fiorina, F. Folli, A. D'Angelo, G. Finzi, F. Pellegatta, V. Guzzi, C. Fedeli, P. D. Valle, L. Usellini, C. Placidi, et al.
Normalization of Multiple Hemostatic Abnormalities in Uremic Type 1 Diabetic Patients After Kidney-Pancreas Transplantation
Diabetes, September 1, 2004; 53(9): 2291 - 2300.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
E. Vericel, C. Januel, M. Carreras, P. Moulin, and M. Lagarde
Diabetic Patients Without Vascular Complications Display Enhanced Basal Platelet Activation and Decreased Antioxidant Status
Diabetes, April 1, 2004; 53(4): 1046 - 1051.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. A. Creager, T. F. Luscher, F. Cosentino, and J. A. Beckman
Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part I
Circulation, September 23, 2003; 108(12): 1527 - 1532.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
M. Laakso and J. Kuusisto
Diabetology for cardiologists
Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B5 - B13.
[Abstract] [PDF]


Home page
JAMAHome page
J. A. Beckman, M. A. Creager, and P. Libby
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
JAMA, May 15, 2002; 287(19): 2570 - 2581.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. I. Osende, J. J. Badimon, V. Fuster, P. Herson, P. Rabito, R. Vidhun, A. Zaman, O. J. Rodriguez, E. I. Lev, U. Rauch, et al.
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control
J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1307 - 1312.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Barazzoni, M. Zanetti, G. Davanzo, E. Kiwanuka, P. Carraro, A. Tiengo, and P. Tessari
Increased Fibrinogen Production in Type 2 Diabetic Patients without Detectable Vascular Complications: Correlation with Plasma Glucagon Concentrations
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3121 - 3125.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1995 by the American Diabetes Association.